What are the specific efficacy and functions of Platinib/Pujihua?

Pralsetinib (Pralsetinib) is a targeted drug targeting RET gene rearrangement mutations and has significant anti-cancer effects. RET gene rearrangement mutation is a driver mutation in many tumor types, especially in non-small cell lung cancer (NSCLC) and thyroid cancer. Platinib specifically inhibits the tyrosine kinase activity of the RET receptor and blocks its signal transduction, thereby inhibiting the proliferation and metastasis of tumor cells.

One of the main efficacy of platinib is the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for transfection rearrangement (RET) gene fusion. For these patients, traditional chemotherapy or immunotherapy may have limited effect. Platinib, as a targeted therapy drug, can effectively inhibit tumor growth and improve treatment effect by directly targeting RET gene mutations.

In addition, platinib is also widely used to treat patients with advanced or metastatic RET-mutated medullary thyroid carcinoma (MTC) who require systemic treatment. Medullary thyroid cancer is a malignant thyroid tumor with a high fatality rate. Platinib can effectively inhibit the proliferation of cancer cells, thus improving the survival rate of patients.

For those patients with advanced or metastatic thyroid cancer that is refractory to radioactive iodinePRET fusion-positive thyroid cancer, platinib also shows good therapeutic effects. Fusion mutations in the RET gene cause these patients to have faster disease progression, and the emergence of platinib provides a new treatment option for these patients.

Overall, platinib, as a new type of targeted drug, provides an effective method to treat cancers associated with RET gene mutations. It has not only made breakthroughs in the treatment of non-small cell lung cancer, medullary thyroid cancer and other fields, but also brought new hope to many patients for whom traditional treatments are difficult to respond.

Keyword tags: Pralsetinib, Pralsetinib, RET gene, targeted drugs, non-small cell lung cancer, medullary thyroid cancer, cancer treatment, gene mutation

Reference materials:https://www.medicines.org.uk/emc/product/13770/smpc